Adoptive therapy of malignant diseases with tumor-specific cytotoxic T cells showed remarkable efficacy in recent trials. Repetitive T cell receptor (TCR) engagement of target antigen, however, inevitably ends up in hypo-responsive cells with terminally differentiated KLRG-1+ CD57+ CD7？ phenotype limiting their therapeutic efficacy. We here revealed that hypo-responsiveness of CMV-specific late-stage CD8+ T cells is due to reduced TCR synapse formation compared to younger cells. Membrane anchoring of TCR components contributes to T cell hypo-responsiveness since dislocation of galectin-3 from the synapse by swainsonine restored both TCR synapse formation and T cell response. Transgenic expression of a CD3-zeta signaling chimeric antigen receptor (CAR) recovered hypo-responsive T cells to full effector functions indicating that the defect is restricted to TCR membrane components while synapse formation of the transgenic CAR was not blocked. CAR engineered late-stage T cells released cytokines and mediated redirected cytotoxicity as efficiently as younger effector T cells. Our data provide a rationale for TCR independent, CAR mediated activation in the adoptive cell therapy to avoid hypo-responsiveness of late-stage T cells upon repetitive antigen encounter.
References
[1]
Park TS, Rosenberg SA, Morgan RA (2011) Treating cancer with genetically engineered T cells. Trends Biotechnol 29: 550–557.
[2]
Klebanoff CA, Acquavella N, Yu Z, Restifo NP (2011) Therapeutic cancer vaccines: are we there yet? Immunol Rev 239: 27–44.
[3]
Fooksman DR, Vardhana S, Vasiliver-Shamis G, Liese J, Blair DA, et al. (2010) Functional anatomy of T cell activation and synapse formation. Annu Rev Immunol 28: 79–105.
[4]
Dustin ML, Chakraborty AK, Shaw AS (2010) Understanding the structure and function of the immunological synapse. Cold Spring Harb Perspect Biol 2: a002311.
[5]
Garber K (2011) Beyond ipilimumab: new approaches target the immunological synapse. J Natl Cancer Inst 103: 1079–1082.
[6]
Turtle CJ, Riddell SR (2011) Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. Curr Opin Immunol 23: 299–305.
[7]
Rappl G, Schrama D, Hombach A, Meuer EK, Schmidt A, et al. (2008) CD7？ T cells are late memory cells generated from CD7+ T cells. Rejuvenation Res 11: 543–556.
[8]
Simpson RJ, Cosgrove C, Chee MM, Mc Farlin BK, Bartlett DB, et al. (2010) Senescent phenotypes and telomere lengths of peripheral blood T cells mobilized by acute exercise in humans. Exerc Immunol Rev 16: 40–55.
[9]
Neeson P, Shin A, Tainton KM, Guru P, Prince HM, et al. (2010) Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Therapy 17: 1105–1116.
[10]
Larbi A, Pawelec G, Wong SC, Goldeck D, Tai JJ, et al. (2011) Impact of age on T cell signaling: a general defect or specific alterations? Ageing Res Rev 10: 370–378.
[11]
Vazquez-Cintron EJ, Monu NR, Frey AB (2010) Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase. J Immunol 185: 7133–7140.
[12]
Ramos CA, Dotti G (2011) Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther 11: 855–873.
[13]
Roszik J, Sebestyen Z, Govers C, Guri Y, Sz？？r A, et al. (2011) T cell synapse formation depends on antigen recognition but not CD3 interaction: studies with TCR:zeta, a candidate transgene for TCR gene therapy. Eur J Immunol 41: 1288–1297.
[14]
Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, et al. (2010) The optimal antigen response of chimeric antigen receptors harboring the CD3-zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol 184: 6938–6949.
[15]
Hsu DK, Chen HY, Liu FT (2009) Galectin-3 regulates T cell functions. Immunol Rev 230: 114–127.
[16]
Powell DJ Jr, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA (2006) Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 177: 6527–6539.
[17]
Arnold CR, Wolf J, Brunner S, Herndler-Brandstetter D, Grubeck-Loebenstein B (2011) Gain and loss of T cell subsets in old age-age-related reshaping of the T cell repertoire. J Clin Immunol 31: 137–146.
[18]
Buchholz VR, Neuenhahn M, Busch DH (2011) CD8+ T cell differentiation in the aging immune system: until the last clone standing. Curr Opin Immunol 23: 549–554.
[19]
Boding L, Bonefeld CM, Nielsen BL, Lauritsen JPH, von Essen MR, et al. (2009) TCR down-regulation controls T cell homeostasis. J Immunol 183: 4994–5005.
[20]
Chen HY, Fermin A, Vardhana S, Weng IC, Lo KFR, et al. (2009) Galectin-3 negatively regulates TCR-mediated CD4+ T cell activation at the immunological synapse. Proc Natl Acad Sci 106: 14496–14501.
[21]
Demotte N, Wie？rs G, van der Smissen P, Moser M, Schmidt C, et al. (2010) A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res 70: 7476–7488.
[22]
Stillman BN, Hsu DK, Pang M, Brewer CF, Johnson P, et al. (2006) Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 176: 778–789.
[23]
Grigorian A, Demetriou M (2010) Manipulating cell surface glycoproteins by targeting N-glycan-galectin interactions. Methods Enzymol 480: 245–266.
[24]
Linnemann C, Schumacher TN, Bendle GM (2011) T cell receptor gene therapy: critical parameters for clinical success. J Invest Dermatol 131: 1806–1816.
[25]
Jorritsma A, Schotte R, Coccoris M, de Witte MA, Schumacher TN (2011) Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther 11: 276–287.
[26]
Bartelt RR, Cruz-Orcutt N, Collins M, Houtman JCD (2009) Comparison of T cell receptor-induced proximal signaling and downstream functions in immortalized and primary T cells. PLoS ONE 4: e5430.
[27]
Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, et al. (2009) Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 69: 8412–8419.
[28]
Ma H, Zhou Z, Wei S, Liu Z, Pooley KA, et al. (2011) Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS ONE 6: e20466.
[29]
Debes GF, Arnold CN, Young AJ, Krautwald S, Lipp M, et al. (2005) Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat Immunol 6: 889–894.
[30]
Weiner HL, da Cunha AP, Quintana F, Wu H (2011) Oral tolerance. Immunol Rev 241: 241–259.
[31]
Ohno-Iwashita Y, Shimada Y, Hayashi M, Inomata M (2010) Plasma membrane microdomains in aging and disease. Geriatr Gerontol Int 10: Suppl 1S41–52.
[32]
Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, et al. (2011) Intrinsic and extrinsic control of peripheral T cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev 241: 180–205.
[33]
Effros RB (2011) Telomere/telomerase dynamics within the human immune system: effect of chronic infection and stress. Exp Gerontol 46: 135–140.
[34]
Hombach A, Heuser C, Abken H (2003) Generation, expression, and monitoring of recombinant immune receptors for use in cellular immunotherapy. Methods Mol Biol 207: 365–381.
[35]
Kaulen H, Seemann G, Bosslet K, Schwaeble W, Dippold W (1993) Humanized anti-carcinoembryonic antigen antibody: strategies to enhance human tumor cell killing. Year Immunol 7: 106–109.
[36]
Tavano R, Contento RL, Baranda SJ, Soligo M, Tosto L, et al. (2006) CD28 interaction with filamin-A controls lipid raft accumulation at the T cell immunological synapse. Nature Cell Biology 8: 1270–1276.
